Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 15.9%, EPS grew 38.1%, free cash flow grew 211.3% and total debt rose 6.44%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow XGN
Exagen Inc. (XGN) P/E ratio
Exagen Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 27 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BNR Burning Rock Biotech Limited Sponsored ADR compare | n/m |
| MDXHF MedX Health Corp. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | n/m |
| BDSX Biodesix, Inc. compare | n/m |
| FLGT Fulgent Genetics, Inc. compare | n/m |
| QUCY Quantum Cyber N.V compare | n/m |
| MDXH MDxHealth SA compare | n/m |
| XGN Exagen Inc. | n/m |
| IMDX Insight Molecular Diagnostics Inc. compare | n/m |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)